Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, K. L. Blackwell, E. P. Winer, W. Janni, S. Verma, P. Conte, C. L. Arteaga, D. A. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. GermaJ. O'Shaughnessy

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))'. Together they form a unique fingerprint.

Medicine & Life Sciences